[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100642745":3},{"organization":4,"armGroups":7,"interventions":29,"overallOfficials":10,"centralContacts":46,"locations":55,"responsibleParty":85,"collaborators":10,"id":89,"slug":90,"hasResults":91,"nctId":92,"briefTitle":93,"officialTitle":93,"acronym":94,"eligibilityCriteria":95,"healthyVolunteers":91,"sex":96,"minAge":97,"maxAge":10,"enrollmentInfo":98,"targetDuration":101,"studyType":102,"phases":10,"briefSummary":103,"conditions":104,"keywords":109,"overallStatus":120,"whyStopped":10,"lastUpdateSubmitDate":121,"lastUpdatePostDateStruct":122,"startDateStruct":125,"completionDateStruct":127,"leadSponsor":129,"locationsCount":130},{"fullName":5,"class":6},"University of Pittsburgh","OTHER",[8,17,21,25],{"label":9,"type":10,"description":11,"interventionNames":12},"High KDPI",null,"Adult end stage kidney disease patients who received a recent deceased donor kidney transplant with High KDPI allografts",[13,14,15,16],"Diagnostic Test: Ultrasound contrast agent (Contrast-enhanced ultrasound)","Drug: Optison (Perflutren Protein-Type A Microspheres Injectable Suspension)","Drug: Lumason® contrast agent","Drug: DEFINITY®",{"label":18,"type":10,"description":19,"interventionNames":20},"Low KDPI","Adult end stage kidney disease patients who received a recent deceased donor kidney transplant with Low KDPI allografts",[13,14,15,16],{"label":22,"type":10,"description":23,"interventionNames":24},"Delayed Graft Function","Adult end stage kidney disease patients who received a recent deceased donor kidney transplant who require renal replacemen therapy within 2 weeks after transplant.",[13,14,15,16],{"label":26,"type":10,"description":27,"interventionNames":28},"Non-delayed Graft Function","Adult end stage kidney disease patients who received a recent deceased donor kidney transplant who do not require renal replacemen therapy within 2 weeks after transplant.",[13,14,15,16],[30,35,40,43],{"type":31,"name":32,"description":33,"armGroupLabels":34,"otherNames":10},"DIAGNOSTIC_TEST","Ultrasound contrast agent (Contrast-enhanced ultrasound)","Super-resolution ultrasound using lipid microsphere contrast",[22,9,18,26],{"type":36,"name":37,"description":38,"armGroupLabels":39,"otherNames":10},"DRUG","Optison (Perflutren Protein-Type A Microspheres Injectable Suspension)","Approved drug or biologic being evaluated for a new indication, population, route of administration, or dosage level not specified in the FDA approved labeling for kidney imaging.",[22,9,18,26],{"type":36,"name":41,"description":38,"armGroupLabels":42,"otherNames":10},"Lumason® contrast agent",[22,9,18,26],{"type":36,"name":44,"description":38,"armGroupLabels":45,"otherNames":10},"DEFINITY®",[22,9,18,26],[47,52],{"name":48,"role":49,"phone":50,"phoneExt":10,"email":51},"Roderick J Tan, MD, PHD","CONTACT","4126244008","Tanrj@upmc.edu",{"name":53,"role":49,"phone":10,"phoneExt":10,"email":54},"George F Viriya, MD","viriyagf@upmc.edu",[56],{"facility":57,"status":10,"city":58,"state":59,"zip":60,"country":61,"countryCode":62,"cosmosGeoPoint":63,"geoPoint":68,"contacts":69},"University of Pittsburgh Medical Center","Pittsburgh","Pennsylvania","15213","United States","US",{"type":64,"coordinates":65},"Point",[66,67],-79.99589,40.44062,{"lat":67,"lon":66},[70,73,75,78,79,81,83],{"name":53,"role":49,"phone":71,"phoneExt":10,"email":72},"9177480056","gviriya@gmail.com",{"name":48,"role":49,"phone":50,"phoneExt":10,"email":74},"tanrj@upmc.edu",{"name":76,"role":77,"phone":10,"phoneExt":10,"email":10},"Kang Kim, PHD","SUB_INVESTIGATOR",{"name":53,"role":77,"phone":10,"phoneExt":10,"email":10},{"name":48,"role":80,"phone":10,"phoneExt":10,"email":10},"PRINCIPAL_INVESTIGATOR",{"name":82,"role":77,"phone":10,"phoneExt":10,"email":10},"Mohit Madken, MD",{"name":84,"role":77,"phone":10,"phoneExt":10,"email":10},"Jihoon Park, MD, PHD",{"type":86,"investigatorFullName":87,"investigatorTitle":88,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"SPONSOR_INVESTIGATOR","Roderick Tan","Associate Professor","100642745","microvasculature-ultrasound-super-resolution-in-transplant-delayed-graft-function-100642745",false,"NCT07645599","Microvasculature Ultrasound Super-resolution in Transplant Delayed Graft Function","MUST-D","Inclusion Criteria:\n\nFor stage 1 of the study:\n\n1. We will enroll patients ≥18 years of age\n2. Patients who received a kidney transplant 2a. Patients requiring dialysis in the first 14 days after transplant 2b. Patients with working allografts not requiring dialysis (control group)\n\nFor stage 2 of the study\n\n1. We will enroll patients at least 18 years of age or older\n2. Patients who received a kidney transplant 2a. Patients who received kidney transplants from low KDPI kidneys (KDPI \\\u003C 35) 2b. Patients who received kidney transplants from high KDPI kidneys (KDPI \\> 75)\n\nExclusion Criteria:\n\n1. BMI \\> 40\n2. Inability to provide informed consent\n3. Pregnant woman\n4. Breastfeeding women\n5. Hypersensitivity to perfluten lipid microsphere and components including polyethylene glycol (PEG)\n6. Unstable cardiopulmonary condition (acute myocardial infarction, acute coronary artery symptoms, worsening or unstable congestive heart failure, serious ventricular arrhythmias).\n7. Known history of cardiac shunts\n8. Patients who have known sickle cell disease or trait","ALL","18 Years",{"count":99,"type":100},40,"ESTIMATED","3 Years","OBSERVATIONAL","This pilot study is testing a new ultrasound imaging method called Super-Resolution Ultrasound (SRU) to look at blood flow and tiny blood vessels in transplanted kidneys in very detailed images after kidney transplant surgery. The goal is to see whether changes in the kidney's small blood vessels can help predict how well the transplanted kidney will work early after transplant, including whether delayed graft function may occur.\n\nInvestigators hope this technique can become a safe, noninvasive way to evaluate transplanted kidneys without needing as many invasive biopsies. It may also help doctors better assess donor kidneys at higher-risk of suboptimal functioning.",[105,106,107,108],"End Stage Chronic Renal Failure","Renal Transplant","Microvascular Changes","Microvascular Circulation",[110,111,112,113,114,115,116,117,118,119],"renal allograft","kidney allograft","kidney transplant","super-resolution ultrasound","lipid microspheres","renal microvasculature","kidney microvasculature","delayed graft function","Kidney Donor Profile Index","deceased donor kidney transplant","NOT_YET_RECRUITING","2026-06-08",{"date":123,"type":124},"2026-06-12","ACTUAL",{"date":126,"type":100},"2026-06-01",{"date":128,"type":100},"2028-06-30",{"name":87,"class":6},1]